ÌÇÐÄvlog

[Skip to Navigation]
Sign In

October 2024 - July 1959

Decade

Year

Issue

December 2023, Vol 80, No. 12, Pages 1262-1379

Viewpoint

Antiplatelets Are Enough for Nondisabling Strokes

Abstract Full Text
JAMA Neurol. 2023;80(12):1263-1264. doi:10.1001/jamaneurol.2023.3994

This Viewpoint argues, in keeping with current stroke management guidelines, that patients with mild, nondisabling strokes should not receive thrombolysis, even when presenting within the time window for treatment.

On the Brain

I Do Care

Abstract Full Text
JAMA Neurol. 2023;80(12):1265. doi:10.1001/jamaneurol.2023.3629

This essay recalls the importance of compassion in medicine.

Editorial

Looking for Atrial Fibrillation With Insertable Cardiac Monitors—Is 1 Year Long Enough and Does it Matter?

Abstract Full Text
JAMA Neurol. 2023;80(12):1266-1268. doi:10.1001/jamaneurol.2023.3377

APOE Genotype in the Era of Disease-Modifying Treatment With Monoclonal Antibodies Against Amyloid-β

Abstract Full Text
JAMA Neurol. 2023;80(12):1269-1271. doi:10.1001/jamaneurol.2023.4046

Brexpiprazole for the Treatment of Agitation and Aggression in Alzheimer Disease

Abstract Full Text
JAMA Neurol. 2023;80(12):1272-1273. doi:10.1001/jamaneurol.2023.3967

Time to Treat the Climate and Nature Crisis as One Indivisible Global Health Emergency

Abstract Full Text
free access
JAMA Neurol. 2023;80(12):1274-1276. doi:10.1001/jamaneurol.2023.4644
Original Investigation

Atrial Fibrillation In Patients With Stroke Attributed to Large- or Small-Vessel Disease: 3-Year Results From the STROKE AF Randomized Clinical Trial

Abstract Full Text
open access has audio
JAMA Neurol. 2023;80(12):1277-1283. doi:10.1001/jamaneurol.2023.3931

This study compares the rates of atrial fibrillation detection through 3 years of follow-up between an insertable cardiac monitor vs site-specific usual care, in patients with prior ischemic stroke attributed to large-artery disease or small-vessel disease.

APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry

Abstract Full Text
open access
JAMA Neurol. 2023;80(12):1284-1294. doi:10.1001/jamaneurol.2023.3599

This genetic association study assesses associations between apolipoprotein E and Alzheimer disease risk across age, sex, race and ethnicity, and global population ancestry.

ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels

Abstract Full Text
free access
JAMA Neurol. 2023;80(12):1295-1306. doi:10.1001/jamaneurol.2023.4038

This cohort study evaluates amyloid-related tau spreading in apolipoprotein E ε4 carriers and amyloid positron emission tomography thresholds at which tau spreading may accelerate.

Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial

Abstract Full Text
open access
JAMA Neurol. 2023;80(12):1307-1316. doi:10.1001/jamaneurol.2023.3810

This randomized clinical trial examines data for patients with Alzheimer dementia to determine whether brexpiprazole is an efficacious, safe, and well-tolerated treatment for agitation.

Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis

Abstract Full Text
free access has audio
JAMA Neurol. 2023;80(12):1317-1325. doi:10.1001/jamaneurol.2023.3997

This cohort study investigates the timing of neuroaxonal pathology in individuals with multiple sclerosis who experience disability worsening.

Association Between Slow-Wave Sleep Loss and Incident Dementia

Abstract Full Text
free access
JAMA Neurol. 2023;80(12):1326-1333. doi:10.1001/jamaneurol.2023.3889

This cohort study examines data from a sample of participants in the Framingham Heart Study who completed 2 overnight polysomnography studies to assess whether reductions in slow-wave sleep are associated with the risk of incident dementia.

Safety and Efficacy of Topiramate in Individuals With Cryptogenic Sensory Peripheral Neuropathy With Metabolic Syndrome: The TopCSPN Randomized Clinical Trial

Abstract Full Text
free access
JAMA Neurol. 2023;80(12):1334-1343. doi:10.1001/jamaneurol.2023.3711

This randomized clinical trial investigates if topiramate slows decline in intraepidermal nerve fiber density and/or improves neuropathy-specific quality of life in individuals with cryptogenic sensory peripheral neuropathy and concurrent metabolic syndrome.

Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial

Abstract Full Text
free access
JAMA Neurol. 2023;80(12):1344-1352. doi:10.1001/jamaneurol.2023.3861

This randomized clinical trial examines data from patients with mild Alzheimer disease receiving BIIB080 to assess changes in tau biomarkers associated with cognitive decline, including cerebrospinal fluid total tau and phosphorylated tau 181 and tau positron emission tomography.

Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease

Abstract Full Text
free access
JAMA Neurol. 2023;80(12):1353-1363. doi:10.1001/jamaneurol.2023.3618

This cohort study investigates whether white matter hyperintensity in individuals with Alzheimer disease is more likely to be associated with neurodegeneration and parenchymal and vessel amyloidosis than with systemic vascular risk.

Special Communication

A New Framework for Dementia Nomenclature

Abstract Full Text
has active quiz
JAMA Neurol. 2023;80(12):1364-1370. doi:10.1001/jamaneurol.2023.3664

This Special Communication describes the need for a systematic neurodegenerative disease framework for information collection and communication to standardize dementia nomenclature usage for research, clinical, and public health purposes.

Images in Neurology

Histologic Anatomy of Neurocysticercosis

Abstract Full Text
has active quiz
JAMA Neurol. 2023;80(12):1371-1372. doi:10.1001/jamaneurol.2023.3739

This case report describes a 23-year-old male patient with tonic-clonic seizure and subsequent treatment with anthelmintic therapy.

Selfie-Induced Diagnostic Challenge in Horner Syndrome

Abstract Full Text
has active quiz
JAMA Neurol. 2023;80(12):1373-1374. doi:10.1001/jamaneurol.2023.3884

This case report describes an 18-year-old woman with neurofibromatosis type 1 and prior right brachial plexus neurofibroma resection who reported intermittent, unilateral facial flushing after exertion.

JAMA Neurology Clinical Challenge

Progressive Cranial Neuropathy

Abstract Full Text
has active quiz
JAMA Neurol. 2023;80(12):1375-1376. doi:10.1001/jamaneurol.2023.3706

A 68-year-old man had right facial weakness with a droop, slurred speech, and eyelid ptosis that progressed over 5 years from right temple numbness and did not respond to gabapentin or steroids. What is your diagnosis?

Research Letter

Ongoing Challenges in the Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

Abstract Full Text
open access
JAMA Neurol. 2023;80(12):1377-1379. doi:10.1001/jamaneurol.2023.3956

This cross-sectional study examines whether proposed myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) diagnostic criteria can exclude other diseases, such as multiple sclerosis, and rely on results of cell-based assays.

Correction

Error in Figure 1

Abstract Full Text
free access
JAMA Neurol. 2023;80(12):1379. doi:10.1001/jamaneurol.2023.4287
JAMA Neurology Masthead

JAMA Neurology

Abstract Full Text
free access
JAMA Neurol. 2023;80(12):1262. doi:10.1001/jamaneurol.2022.4109
×